Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects

被引:112
|
作者
Doose, DR
Wang, SS
Padmanabhan, M
Schwabe, S
Jacobs, D
Bialer, T
机构
[1] Hebrew Univ Jerusalem, Dept Pharmaceut, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
topiramate; carbamazepine; ethinyl estradiol; norethidrone; obesity;
D O I
10.1046/j.1528-1157.2003.55602.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To study the pharmacokinetics of a combination oral contraceptive (OC) containing norethindrone and ethinyl estradiol during OC monotherapy, concomitant OC and topiramate (TPM) therapy, and concomitant OC and carbamazepine (CBZ) therapy in order to comparatively evaluate the pharmacokinetic interaction, which may cause contraceptive failure. Methods: This randomized, open-label, five-group study included two 28-day cycles. Five groups of female subjects received oral doses of ORTHO-NOVUM 1/35 alone (cycle 1) and then concomitant with TPM or CBZ (cycle 2). The treatment groups were group 1, TPM, 50 mg/day; group 2, TPM, 100 mg/day; group 3, TPM, 200 mg/day; group 4, TPM, 200 mg/day (obese women); and group 5, CBZ, 600 mg/day. Group 4 comprised obese women whose body mass index (BMI) was between 30 and 35 kg/m(2). The BMI of the remaining four groups was less than or equal to27 kg/m(2). Results: Coadministration of TPM at daily doses of 50, 100, and 200 mg (nonobese) and 200 mg (obese) nonsignificantly (p > 0.05) changed the mean area under the curve (AUC) of ethinyl estradiol by -12%, +5%, -11%, and -9%, respectively, compared with OC monotherapy. A similar nonsignificant difference was observed with the plasma levels and AUC values of norethindrone (p > 0.05). CBZ (600 mg/day) significantly (p < 0.05) decreased the AUC values of norethindrone and ethinyl estradiol by 58% and 42%, respectively, and increased their respective oral clearance by 69% and 127% (p < 0.05). Because CBZ induces CYP 3A-mediated and glucuronide conjugation metabolic pathways, the significant increase in the oral clearance of ethinyl estradiol and norethindrone was anticipated. Conclusions: TPM, at daily doses of 50-200 mg, does not interact with an OC containing norethindrone and ethinyl estradiol. The lack of the TPM-OC interaction is notable when it is compared with the CBZ-OC interaction.
引用
收藏
页码:540 / 549
页数:10
相关论文
共 50 条
  • [21] Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen®, a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women
    Upreti, V. V.
    Hsiang, C. B.
    Li, L.
    Xu, X.
    LaCreta, F. P.
    Boulton, D. W.
    DIABETES OBESITY & METABOLISM, 2012, 14 (12): : 1155 - 1157
  • [22] GLUCOSE AND INSULIN LEVELS AFTER 6 MONTHS OF TREATMENT WITH A TRIPHASIC ORAL-CONTRACEPTIVE CONTAINING ETHINYL ESTRADIOL AND NORETHINDRONE
    SPELLACY, WN
    ELLINGSON, AB
    TSIBRIS, JCM
    JOURNAL OF REPRODUCTIVE MEDICINE, 1989, 34 (08) : 540 - 542
  • [23] Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women
    Trezza, Christine
    Ford, Susan L.
    Gould, Elizabeth
    Lou, Yu
    Huang, Chuyun
    Ritter, James M.
    Buchanan, Ann M.
    Spreen, William
    Patel, Parul
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (07) : 1499 - 1505
  • [24] Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females
    Trapnell, Carol Braun
    Connolly, Margaret
    Pentikis, Helen
    Forbes, William P.
    Bettenhausen, Doug K.
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (02) : 222 - 228
  • [25] A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol
    Reisman, H
    Martin, D
    Gast, MJ
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) : S45 - S52
  • [26] Effect of oral siponimod (BAF312) on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female subjects
    Biswal, S.
    Veldandi, U. K.
    Derne, C.
    Golla, G.
    Muhsen, N.
    Shakeri-Nejad, K.
    Legangneux, E.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 271 - 272
  • [27] Effect of oral siponimod (BAF312) on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female subjects
    Biswal, Shibadas
    Veldandi, Uday Kiran
    Derne, Caroline
    Golla, GangaRaju
    Muhsen, Naguib
    Legangneux, Eric
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (11) : 996 - 1004
  • [28] Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women
    Sivasubramanian, Rama
    Chakraborty, Abhijit
    Rouzade-Dominguez, Marie-Laure
    Neelakantham, Srikanth
    Jakab, Annamaria
    Mensinga, Tjeert
    Legangneux, Eric
    Woessner, Ralph
    Ufer, Mike
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (07) : 550 - 556
  • [29] Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects
    Chen, Jin
    Bhansali, Suraj
    Neelakantham, Srikanth
    Trusley, Craig
    Majumdar, Tapan
    Rebello, Sam
    Sunkara, Gangadhar
    Meyers, Charles
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (04) : 317 - 324
  • [30] The effect of rifaximin on the pharmacokinetics of a single dose of ethinyl estradiol and norgestimate in healthy female volunteers.
    King, A
    Marshall, O
    Connolly, M
    Kamm, A
    Boxenbaum, H
    Kastrissios, H
    Trapnell, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P96 - P96